Hamilton, ON & Boston, MA – January 10, 2020 – Fusion Pharmaceuticals Inc., a privately-held, clinical-stage precision oncology company developing next-generation radiopharmaceuticals, today announced that Chief Executive Officer John Valliant, Ph.D., will present an overview of the Company at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California. The presentation will take place on Thursday, January 16, 2020 at 11:00am PST.
About Fusion Pharmaceuticals, Inc.
Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted alpha therapeutics to treat cancer. Using its proprietary Fast-Clear™ Linker Technology platform, Fusion attaches medical isotopes to targeting molecules creating novel, next-generation cancer treatments. In preclinical studies, the Company has shown the ability to precisely target and effectively kill solid tumor cells while minimizing the impact to healthy tissue. Fusion’s lead program, FPI-1434, is currently in a Phase 1 trial.
With a proprietary discovery platform, Fusion is actively in-licensing targeting molecules and forming strategic partnerships to expand its pipeline of cancer therapies. For more information, please visit www.fusionpharma.com or contact info@fusionpharma.com.
Contact:
Amanda Cray
Senior Director of Investor Relations & Corporate Communications
617-420-5698
cray@fusionpharma.com
